Enanta Pharmaceuticals Files 8-K Report

Ticker: ENTA · Form: 8-K · Filed: Dec 9, 2024 · CIK: 1177648

Enanta Pharmaceuticals Inc 8-K Filing Summary
FieldDetail
CompanyEnanta Pharmaceuticals Inc (ENTA)
Form Type8-K
Filed DateDec 9, 2024
Risk Levellow
Pages5
Reading Time7 min
Key Dollar Amounts$0.01
Sentimentneutral

Sentiment: neutral

Topics: 8-K, regulatory-filing, financials

TL;DR

ENANTA filed an 8-K. Standard regulatory update, no major news in this snippet.

AI Summary

On December 9, 2024, Enanta Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial statements and exhibits. No specific material events or financial figures were detailed in the provided excerpt.

Why It Matters

This filing indicates Enanta Pharmaceuticals is making a regulatory disclosure and providing updates on other events and financial information to the SEC.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report for disclosures and financial statements, not indicating any immediate negative events.

Key Players & Entities

  • ENANTA PHARMACEUTICALS INC (company) — Registrant
  • December 9, 2024 (date) — Date of earliest event reported
  • 0001177648 (company) — Central Index Key
  • 4 Kingsbury Avenue Watertown, Massachusetts 02472 (address) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The filing serves as a Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, covering Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.

When was the earliest event reported in this filing?

The earliest event reported is dated December 9, 2024.

What is Enanta Pharmaceuticals' principal executive office address?

Enanta Pharmaceuticals' principal executive offices are located at 4 Kingsbury Avenue, Watertown, Massachusetts 02472.

What is Enanta Pharmaceuticals' Central Index Key (CIK)?

Enanta Pharmaceuticals' Central Index Key is 0001177648.

Under which state was Enanta Pharmaceuticals incorporated?

Enanta Pharmaceuticals was incorporated in Delaware.

Filing Stats: 1,638 words · 7 min read · ~5 pages · Grade level 13.5 · Accepted 2024-12-09 08:29:32

Key Financial Figures

  • $0.01 — ich registered Common Stock, par value $0.01 per share ENTA Nasdaq Global Select

Filing Documents

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K includes forward-looking statements, including with respect to the prospects for further development and advancement of zelicapavir for the treatment of RSV. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this report are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage discovery efforts in the disease areas in Enanta's research and development pipeline, such as RSV; the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; Enanta's limited clinical development experience; Enanta's need to attract and retain senior management and research and development personnel; Enanta's need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in "Risk Factors" in Enanta's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this report. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect eve

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press release dated December 9, 2024 99.2 Slide presentation entitled "Phase 2 Study of Zelicapavir in Children: RSVPEDs Topline Results" 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 9, 2024 ENANTA PHARMACEUTICALS, INC. By: /s/ Paul J. Mellett Paul J. Mellett Chief Financial and Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.